Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)

Award Number: R24AI120942
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2016
PERIOD OF PERFORMANCE END DATE: 03/24/2025
AWARD TERMINATION DATE: 03/26/2025

Group Awards By:

View Award Description

World Reference Center for Emerging Viruses and Arboviruses (WRCEVA) - ABSTRACT As underscored by pandemic COVID-19, Zika, yellow fever and chikungunya viruses, new and emerging viruses represent increasing threats to human health, yet their mechanisms of emergence remain poorly understood, and effective interventions are not available for most. Research on their pathogenesis, ecology, evolution, epidemiology, emergence mechanisms, diagnostics, vaccines and therapeutics remain critical public health needs. The World Reference Center for Emerging Viruses and Arboviruses (WRCEVA) comprises a comprehensive, diverse collection of over 8,000 virus strains in 21 families, as well as antisera, antigens, cDNA clones and other reagents to enable research worldwide. Approximately 400 new virus strains are added annually, and 1000 viruses and reagents are shipped annually. The WRCEVA also maintains broad expertise in both novel and traditional approaches to virus identification and characterization, and provides critical support for emergency outbreak responses as exemplified by the rapid generation and distribution of critical COVID and Zika reagents. This proposal seeks to continue these WRCEVA activities in support of NIH-funded and other research on emerging viruses worldwide, through five Specific Aims: 1. Maintain a comprehensive set of emerging viruses, arboviruses and associated reagents to support research and surveillance. The virus collection as well as antigens, antibodies, cDNA clones and other reagents will be continually enhanced to capitalize on new emergence trends and technologies. Emphasis during the first two years will be placed on the development of critical reagents for coronavirus research. 2. Discover, isolate and characterize newly acquired viruses to determine relationships and taxonomic assignments, and to assess in vitro and in vivo host range. Clinical and field samples as well as viral isolates will be received for identification and characterization, and added to the repository. Critical phenotypes of newly discovered viruses and strains will be assessed by using in vitro and in vivo infections. 3. Perform sequencing and phylogenetic analyses of selected virus groups to determine evolutionary histories and emergence mechanisms, patterns of spread/infection, and to rapidly determine the sources of new outbreaks. Key virus strains will undergo genomic sequencing to generate databases that can be exploited for the rapid determination of new outbreak sources, including potential bioterrorism. 4. Determine why yellow fever virus has not caused major urban epidemics in South America for many decades, or ever in Asia. Our unique collection of virus strains and arbovirology expertise will be used to examine hypotheses related to limitations on urban transmission by Aedes aegypti mosquitoes. 5. Train scientists in the identification and characterization of emerging viruses. To enhance research and surveillance in the U.S. and worldwide, the most efficient way to limit spread of new outbreaks, training in virus identification, characterization, and diagnostics will be provided to visiting scientists.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$1,099,099 )
2026	2024	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	000	9	4/15/2026	TERMINATION	-$1,099,099
														Subtotal = -$1,099,099

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	000	9	3/25/2025	TERMINATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $987,497 )
2024	2024	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	001	9	5/13/2024	NON-COMPETING CONTINUATION	$987,497
2024	2022	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	000	7	4/8/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $987,497

Issue Date FY: 2023 ( Subtotal = $947,243 )
2023	2023	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	001	8	5/25/2023	NON-COMPETING CONTINUATION	$987,497
2023	2020	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	000	5	2/8/2023	NON-COMPETING CONTINUATION	-$40,254
														Subtotal = $947,243

Issue Date FY: 2022 ( Subtotal = $979,028 )
2022	2022	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	000	7	3/30/2022	NON-COMPETING CONTINUATION	$987,497
2022	2020	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	001	5	6/29/2022	SUPPLEMENT FOR EXPANSION	-$8,469
														Subtotal = $979,028

Issue Date FY: 2021 ( Subtotal = $986,347 )
2021	2021	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	003	6	9/28/2021	COMPETING CONTINUATION	$128,211
2021	2021	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	001	6	4/12/2021	COMPETING CONTINUATION	$987,497
2021	2020	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	000	5	4/1/2021	NON-COMPETING CONTINUATION	$0
2021	2020	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	002	5	9/28/2021	NON-COMPETING CONTINUATION	-$128,211
2021	2020	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	004	5	9/28/2021	SUPPLEMENT FOR EXPANSION	-$1,150
														Subtotal = $986,347

Issue Date FY: 2020 ( Subtotal = $1,083,653 )
2020	2020	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	001	5	4/2/2020	SUPPLEMENT FOR EXPANSION	$355,500
2020	2020	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	000	5	1/24/2020	NON-COMPETING CONTINUATION	$728,153
														Subtotal = $1,083,653

Issue Date FY: 2019 ( Subtotal = $742,138 )
2019	2019	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	000	4	2/1/2019	NON-COMPETING CONTINUATION	$742,138
														Subtotal = $742,138

Issue Date FY: 2018 ( Subtotal = $1,074,805 )
2018	2018	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	000	3	1/24/2018	NON-COMPETING CONTINUATION	$1,074,805
														Subtotal = $1,074,805

Issue Date FY: 2017 ( Subtotal = $924,949 )
2017	2017	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	000	2	1/26/2017	NON-COMPETING CONTINUATION	$761,667
2017	2017	UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	301 UNIVERSITY BLVD	GALVESTON	TX	77555	GALVESTON	USA	Allergy and Infectious Diseases Research	001	2	9/1/2017	NON-COMPETING CONTINUATION	$163,282
														Subtotal = $924,949

Issue Date FY: 2016 ( Subtotal = $769,497 )
2016	2016	UNIVERSITY OF TEXAS, MEDICAL BRANCH AT GALVESTON	1000 STRAND	GALVESTON	TX	77550	GALVESTON	USA	Allergy and Infectious Diseases Research	000	1	1/27/2016	NEW	$769,497
														Subtotal = $769,497

Grand Total All Awards = $7,396,058

Top

All Categories

About

Search

Reports

Data Submission

Award Information

World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)

Award Number: R24AI120942

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2016

PERIOD OF PERFORMANCE END DATE: 03/24/2025

AWARD TERMINATION DATE: 03/26/2025

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer